AlloSource enrolls 1st patient in cartilage defect repair study: 3 notes

Biologics

AlloSource enrolled the first patient in a study of its ProChondrix CR for articular cartilage defect repair.

Three things to know:

1. The multi-center trial will investigate ProChondrix CR for the repair of symptomatic articular cartilage defects on the femoral condyle and the patella.

2. ProChondrix CR is a cryopreserved osteochondral allograft. After cryopreservation, ProChondrix CR is designed to deliver high chondrocyte viability for up to two years and help stimulate hyaline cartilage growth.

3. ProChondrix CR's extracellular matrix is intended to provide structural support for cell migration and proliferation along the graft-native tissue line, promoting integration while viable chondrocytes promote cartilage repair by generating proteins that facilitate chondrogenesis.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers